PURPOSE: To evaluate the clinical impact of FDG-PET in staging oesophageal cancer and whether this information improves prognostic stratification. METHODS: Impact was based on comparison of a prospectively recorded pre-PET plan with post-PET treatment in 68 consecutive patients undergoing primary staging. Survival was analysed using the Kaplan-Meier product limit method and the Cox proportional hazards regression model. RESULTS: FDG-PET findings impacted on the management of 27/68 patients (40%): in 12 therapy was changed from curative to palliative and in three from palliative to curative, while in 12 other patients there was a change in the treatment modality or delivery but not in the treatment intent. The median survival was 21 months, with post-PET stage and treatment intent both strongly associated with survival (p<0.001). Conventional stage was not able to clearly stratify this population. CONCLUSION: The use of FDG-PET for primary staging of oesophageal cancer changed the clinical management of more than one-third of patients and provided superior prognostic stratification compared with conventional investigations.
PURPOSE: To evaluate the clinical impact of FDG-PET in staging oesophageal cancer and whether this information improves prognostic stratification. METHODS: Impact was based on comparison of a prospectively recorded pre-PET plan with post-PET treatment in 68 consecutive patients undergoing primary staging. Survival was analysed using the Kaplan-Meier product limit method and the Cox proportional hazards regression model. RESULTS: FDG-PET findings impacted on the management of 27/68 patients (40%): in 12 therapy was changed from curative to palliative and in three from palliative to curative, while in 12 other patients there was a change in the treatment modality or delivery but not in the treatment intent. The median survival was 21 months, with post-PET stage and treatment intent both strongly associated with survival (p<0.001). Conventional stage was not able to clearly stratify this population. CONCLUSION: The use of FDG-PET for primary staging of oesophageal cancer changed the clinical management of more than one-third of patients and provided superior prognostic stratification compared with conventional investigations.
Authors: W F Eddie Lau; David S Binns; Robert E Ware; Shakher Ramdave; Florent Cachin; Alexander G Pitman; Rodney J Hicks Journal: Med J Aust Date: 2005-02-21 Impact factor: 7.738
Authors: P Flamen; A Lerut; E Van Cutsem; W De Wever; M Peeters; S Stroobants; P Dupont; G Bormans; M Hiele; P De Leyn; D Van Raemdonck; W Coosemans; N Ectors; K Haustermans; L Mortelmans Journal: J Clin Oncol Date: 2000-09-15 Impact factor: 44.544
Authors: Werner Kneist; Mathias Schreckenberger; Peter Bartenstein; Frank Grünwald; Katja Oberholzer; Theodor Junginger Journal: World J Surg Date: 2003-08-18 Impact factor: 3.352
Authors: F Montravers; D McNamara; J Landman-Parker; D Grahek; K Kerrou; N Younsi; M Wioland; G Leverger; J N Talbot Journal: Eur J Nucl Med Mol Imaging Date: 2002-06-25 Impact factor: 9.236
Authors: Lawrence R Kleinberg; Paul J Catalano; Arlene A Forastiere; Steven M Keller; Edith P Mitchel; Pramila Rani Anne; Al B Benson Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-18 Impact factor: 7.038
Authors: B E Chatterton; I Ho Shon; A Baldey; N Lenzo; A Patrikeos; B Kelley; D Wong; J E Ramshaw; A M Scott Journal: Eur J Nucl Med Mol Imaging Date: 2008-10-18 Impact factor: 9.236
Authors: Cuong P Duong; Rodney J Hicks; Leann Weih; Elizabeth Drummond; Trevor Leong; Michael Michael; Robert J S Thomas Journal: Eur J Nucl Med Mol Imaging Date: 2006-03-21 Impact factor: 9.236